BRAFnon-V600E more frequently co-occurs with IDH1/2 mutations in adult patients with gliomas than in patients harboring BRAFV600E but without a survival advantage

Peer review reports

Original Submission
6 Mar 2021	Submitted	Original manuscript
25 Mar 2021	Reviewed	Reviewer Report - Miriam Bornhorst
28 Mar 2021	Reviewed	Reviewer Report
19 Apr 2021	Author responded	Author comments - Rong Da
Resubmission - Version 2
19 Apr 2021	Submitted	Manuscript version 2
Resubmission - Version 3
	Submitted	Manuscript version 3
1 May 2021	Reviewed	Reviewer Report - Miriam Bornhorst
Resubmission - Version 4
	Submitted	Manuscript version 4
Publishing
5 May 2021	Editorially accepted
12 May 2021	Article published	10.1186/s12883-021-02224-6

Back to article page